Safety

Curis Unveils Q1 2026 Results May 12

By Daybreak Brief Editorial Team

Curis, Inc., a biotech company known for developing emavusertib, is set to reveal its first quarter 2026 financial results on May 12, 2026. They'll be hosting a conference call and webcast that afternoon to discuss the numbers and future plans. What does it mean for you? If you're an investor or just curious about the latest in biotech, this is your chance to hear directly from Curis about their progress and what they have in store for the future.

Original source Read the full story →
▲ 1,384 voters this week
How we select stories →
More from this briefing
Europe's Dilemma: Navigating Iran War Challenges → Chemours Reports Sales Surge Amid Net Loss → RIVANNA Nominated for MedTech Scale-Up Award → TransDigm Soars with Sales Surge and Acquisitions → AI Heats Up Hungary's Political Showdown → Cumberland Pharma's Bold Move Sparks New Horizons → ADP Offers $1 Billion in Senior Notes → Matson Launches Green Wave with New LNG Ships → Lupin's UCD Drug Approved by FDA → MPLX Expands Amid Income Dip and Growth Plans → Australia Launches $74M Online Terrorism Centre → Unlock Europe's History at Florence Archives → AMOC's Wobble: Europe's Climate Gamechanger → Queer Unions Champion Sex Workers' Rights → Campus IDs to Feature 988 Mental Health Lifeline → Reality Defender Forms AI Ethics Committee → Tragic Fantasy Takes Center Stage → Lebanon Balances Conflict and Peace Talks → Pirelli Launches Futuristic Cyber Tyre in Georgia → Mozambique Faces Tough Economic Challenges Ahead → World Bank Boosts Investor Confidence in Developing Nations →

Get stories like this every morning.

Five-minute intelligence briefing — in your inbox at 6 AM.

Subscribe now →